Defects at the level of the pre-mRNA splicing process represent a major cause of human disease. Approximately 15–50% of all human disease mutations have been shown to alter functioning of basic and auxiliary splicing elements. These elements are required to ensure proper processing of pre-mRNA splicing molecules, with their disruption leading to misprocessing of the pre-mRNA molecule and disease. The splicing process is a complex process, with much still to be uncovered before we are able to accurately predict whether a reported genomic sequence variant (GV) represents a splicing-associated disease mutation or a harmless polymorphism. Furthermore, even when a mutation is correctly identified as affecting the splicing process, there still remains the difficulty of providing an exact evaluation of the potential impact on disease onset, severity and duration. In this review, we provide a brief overview of splicing diagnostic methodologies, from in silico bioinformatics approaches to wet lab in vitro and in vivo systems to evaluate splicing efficiencies. In particular, we provide an overview of how the latest developments in high-throughput sequencing can be applied to the clinic, and are already changing clinical approaches.
Skip Nav Destination
Review Article| February 15 2017
RNA splicing in human disease and in the clinic
- Views Icon Views
- Share Icon Share
Diana Baralle, Emanuele Buratti; RNA splicing in human disease and in the clinic. Clin Sci (Lond) 1 March 2017; 131 (5): 355–368. doi: https://doi.org/10.1042/CS20160211
Download citation file: